Cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab: prophylaxis vs. pre-emptive strategies for prevention

Leuk Lymphoma. 2006 Dec;47(12):2435-6. doi: 10.1080/10428190601090436.
No abstract available

Publication types

  • Comment

MeSH terms

  • Alemtuzumab
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / therapeutic use*
  • Antiviral Agents / therapeutic use
  • Cytomegalovirus Infections / complications*
  • Cytomegalovirus Infections / prevention & control
  • Ganciclovir / therapeutic use
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / complications*
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Sensitivity and Specificity
  • Stem Cell Transplantation
  • Transplantation, Homologous
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antiviral Agents
  • Alemtuzumab
  • Ganciclovir